Full-Time
Technology Product Management Lead
AI, Data & Insights
Posted on 8/18/2026
Johnson & Johnson
10,001+ employees
Global healthcare company offering pharma, devices.
Compensation Overview
$109k - $174.8k/yr
Hopewell Township, NJ, USA
Hybrid
Hybrid role with up to 10% travel to offices in Raritan, New Brunswick, and Horsham, New Jersey/Pennsylvania.
Bachelor's, Master's
 Product (1) |
|---|
Get referred to Johnson & Johnson
See people who can refer or advise you
- A bachelor's degree in computer science, Information Technology, Information Systems, Statistics, Data Science, or an equivalent field of study.
- A minimum of 3 years of diverse experience in data and insights technology product development.
- A proven track record of deploying large language models, artificial intelligence agents, and generative artificial intelligence-powered applications in production.
- Deep expertise in Python, machine learning frameworks such as LangChain, and cloud-native artificial intelligence services.
- Strong understanding of prompt engineering, model fine-tuning, and evaluation metrics.
- Experience integrating generative artificial intelligence into business workflows for measurable impact.
- At least 2 years of experience leading mid-to-large data and insights product teams and delivering results through leadership, influencing, and interdependent partnering.
- At least 2 years of experience designing and implementing data engineering and data science solutions in a fast-paced environment.
- Experience crafting technical solutions for business problems and understanding both business processes and technical solutions.
- Expertise in data management, data modeling, large data lake platforms, and business intelligence visualization technologies such as Tableau and Power BI.
- Ability to communicate effectively, think critically, solve problems creatively and flexibly, exercise judgment in high-pressure situations, and deliver projects efficiently with ambitious timelines.
- Define and communicate product vision and strategy for artificial intelligence and generative-artificial-intelligence-enabled analytics platforms and prioritize features aligned with business strategy.
- Define business value, measure return on investment and business outcomes, and manage total cost of ownership across the product life cycle.
- Drive adoption, retention, and customer satisfaction of data analytics products.
- Coach business and technical product owners on product management methodologies.
- Serve as the Technical Product Owner with hands-on involvement in building artificial intelligence and generative artificial intelligence solutions.
- Architect and implement generative artificial intelligence capabilities using Amazon Web Services and Microsoft Azure technologies, including Bedrock, SageMaker, OpenAI, and Azure Machine Learning.
- Collaborate with data scientists and engineers to build and deploy large language models, retrieval-augmented generation, and agentic workflows.
- Lead development of reusable artificial intelligence components and pipelines for commercial analytics use cases.
- Define product design, development standards, release management, testing, validation, and compliance standards.
- Lead the analytics capabilities roadmap and develop project plans and project management activities.
- Provide application support for analytics platforms through service-level management with application service teams.
- Use Agile methodology to define business needs, translate them into user stories, prioritize the product backlog, and define sprint plans.
- Partner with Technology Services teams on demand planning, effort, timing, delivery, and support of new demand.
- Perform source data analysis and data discovery and synthesize business rules for data acquisition and contextual information creation.
- Ensure business product owner engagement and completion of user acceptance testing.
- Provide technology leadership and deliver commercial data and insights solutions for sales and marketing, market access, and medical functions.
- Measure capabilities against demand volume, complexity, business challenges, and improvement within value streams.
- Drive agile product delivery with measurable outcomes and a fail-fast approach.
- Report product health, technical quality, development, and support-service metrics.
- Manage product life cycles and complete upgrade or decommissioning strategies.
- Pharmaceutical, life sciences, or health care industry experience.
- Knowledge of commercial pharmaceutical business processes, including field alignment, call planning, sales reporting, Medical Affairs, and patient data.
- Experience with pharmaceutical data such as Patient Access Services, syndicated sales and marketing data, customer relationship management, digital, laboratory, hub, claims, and specialty pharmacy data.
- Agile development experience, software development life cycle methodology, risk management including information security, and JIRA.
- Hands-on experience with cloud technologies and expertise in the Amazon Web Services or Microsoft Azure technology stack.
- Experience working in continuous integration and continuous delivery frameworks and DevOps for data science and data engineering solutions.
Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Get referred to Johnson & Johnson
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 sales rose 6.6% to $25.3 billion, and guidance topped $101 billion.
- TECVAYLI's March 2026 approval and TREMFYA's May expansion expand growth before 2027.
- The July 27, 2026 talc deal removes roughly 76,000 claims and litigation expense.
What critics are saying
- Stelara sales fell 55.7% in Q2 2026 as Amgen and Sandoz biosimilars flooded pricing.
- The July 2026 talc settlement still depends on 95% claimant acceptance by 2027.
- A failed talc resolution or mega-verdict forces asbestos-style reserves, capital strain, and dividend pressure.
What makes Johnson & Johnson unique
- J&J owns leading franchises in oncology, immunology, and medtech, spanning hospitals and consumers.
- TECVAYLI plus DARZALEX FASPRO won U.S. approval on March 5, 2026, in earlier-line myeloma.
- TREMFYA's May 28, 2026 label now claims joint-damage inhibition, unlike rival IL-23s.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Remote Work Options
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -4%2 year growth
↓ -2%The European Commission has approved Johnson & Johnson's TECVAYLI (teclistamab) combined with daratumumab for treating adults with relapsed or refractory multiple myeloma who have received at least one prior therapy. The approval, based on Phase 3 data, makes this immunotherapy doublet available as early as second-line treatment. The combination demonstrated statistically significant improvements in progression-free and overall survival versus standard care regimens. The drugs work complementarily, with daratumumab modulating the immune system to enhance T-cell fitness and activation, amplifying teclistamab's ability to kill myeloma cells. Over 90% of patients who were progression-free at six months remained so at three years. The treatment offers an off-the-shelf, steroid-sparing immunotherapy option for patients who often experience shorter remissions with each subsequent therapy line.
Johnson & Johnson's chief executive says the company has a "line of sight to double-digit growth by the end of the decade", driven by three newer drugs: Icotyde, Inlexzo and Rybrevant. The pharmaceutical company spun off its healthcare division Kenvue in May 2023 to focus on pharmaceuticals and medical technology. The strategy appears to be working: J&J's share price has risen 55.5% over the past year, compared to 20.7% for the S&P 500. Second-quarter 2026 revenue climbed 6.6% year-over-year to $25.3 billion, primarily driven by its pharmaceutical segment. Tremfya, a drug for inflammatory bowel disease and psoriasis, saw sales jump 72.5% to $2 billion, whilst Darzalex reached $4.2 billion in sales.
Johnson & Johnson has gained 4.4% over the past five trading days whilst the S&P 500 slipped 0.5%. The stock is up 57.3% over the trailing twelve months. Over the past five years, JNJ's correlation to the S&P 500 has been just 0.16, meaning it moves largely independently of the broad market. This independence delivered an annualised return of 11.8% at 17.5% volatility, compared to the index's 13.2% at 17.2% volatility. The company's operational sales grew 5.6% in the second quarter of 2026, reaching $25.3 billion, even as STELARA declined 55.7% under biosimilar competition. TREMFYA grew 71% and now leads new-patient starts in both ulcerative colitis and Crohn's disease. Over the past year, on days when the S&P 500 fell, JNJ moved approximately 65% in the opposite direction.
Johnson & Johnson will lead an $85 million Series C for Delix Therapeutics at a $190 million pre-money valuation. The biotech develops non-hallucinogenic drugs to promote neuroplasticity in psychiatric patients. J&J's term sheet includes a right of first negotiation following Phase II data from Delix's lead compound, DLX-001. This positions J&J as first in line for potential acquisition discussions. Delix announced positive Phase II results in October 2025, showing rapid and durable reductions in depressive symptoms. The FDA cleared a Phase II design allowing patients to self-administer the compound at home. J&J brings relevant experience through Spravato, its FDA-approved nasal spray for treatment-resistant depression. Delix's at-home dosing model offers scalability that Spravato lacks. The financing has not yet closed.
Johnson & Johnson is set to lead neuroplastogen developer Delix Therapeutics’ $85M Series C round, according to documents reviewed by Psychedelic Alpha.